The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10740 malaria professionals are enjoying the free benefits of MalariaWorld today

Plasmodium vivax

NOT Open Access | The changing risk patterns of Plasmodium vivax malaria in Greece due to climate change

July 21, 2020 - 12:05 -- NOT Open Access
Author(s): 
Trájer AJ
Reference: 
Int J Environ Health Res. 2020 Jul 20:1-26

It has great importance to study the potential effects of climate change on Plasmodium vivax malaria in Greece because the country can be the origin of the spread of vivax malaria to the northern areas. The potential lengths of the transmission seasons of Plasmodium vivax malaria were forecasted for 2041–2060 and 2061–2080 and were combined.

Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function

July 20, 2020 - 16:03 -- Open Access
Author(s): 
Alexandra Martin Ramírez, Carlos Lombardia González, Tamara Soler Maniega, Ángela Gutierrez Liarte, Diego Domingo García, Marta Lanza Suárez, María Josefa Bernal Fernández and José Miguel Rubio
Reference: 
Malaria Journal 2020 19:259, 17 July 2020

Plasmodium vivax malaria is characterized by the presence of dormant liver-stage parasites, called hypnozoites, which can cause malaria relapses after an initial attack. Primaquine, which targets liver hypnozoites, must be used in combination with a schizonticidal agent to get the radical cure. However, relapses can sometimes occur in spite of correct treatment, due to different factors such as a diminished metabolization of primaquine.

NOT Open Access | ast and current biological factors affecting malaria in the low transmission setting of Botswana: A review

July 16, 2020 - 07:58 -- NOT Open Access
Author(s): 
Bango ZA, Tawe L, Muthoga CW, Paganotti GM
Reference: 
Infect Genet Evol. 2020 Jul 12:104458

Malaria continues to be one of the top infectious agents contributing to morbidity and mortality in sub-Saharan Africa. Annually, Botswana accounts only for a small proportion of cases (<<1%). Despite significantly reduced incidence rate, the country still experiences sporadic outbreaks that hamper the goal of malaria elimination. This review evaluated previous and current biological factors that impact malaria in Botswana, specifically focussing on the vectors, the parasite and the host. This was accomplished via a literature review evaluating these variables in Botswana.

An unlabelled probe-based real time PCR and modified semi-nested PCR as molecular tools for analysis of chloroquine resistant Plasmodium vivax isolates from Afghanistan

July 15, 2020 - 15:19 -- Open Access
Author(s): 
Sayed Hussain Mosawi, Abdolhossein Dalimi, Najibullah Safi, Reza Fotouhi-Ardakani, Fatemeh Ghaffarifar and Javid Sadraei
Reference: 
Malaria Journal 2020 19:253, 14 July 2020

Plasmodium vivax resistance to chloroquine (CQ) has been reported from many endemic regions in the world. Plasmodium vivax is responsible for 95% of malaria cases in Afghanistan and CQ is the first-line treatment given for vivax malaria. The pvmdr-1 and pvcrt-o (K10 insertion) genes are possible markers for CQ-resistance in P. vivax isolates. There have been no studies done on the presence or absence of molecular markers for CQ-resistance P. vivax in Afghanistan. The present work aimed to evaluate the frequency of mutations in the pvmdr-1 and K10 insertion in the pvcrt-o genes of P. vivax.

Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017

July 15, 2020 - 15:13 -- Open Access
Author(s): 
Kasama Rakmark, Ghulam R. Awab, Jureeporn Duanguppama, Usa Boonyuen, Arjen M. Dondorp and Mallika Imwong
Reference: 
Malaria Journal 2020 19:251, 14 July 2020

Plasmodium vivax is the predominant Plasmodium species in Afghanistan. National guidelines recommend the combination of chloroquine and primaquine (CQ-PQ) for radical treatment of P. vivax malaria. Artesunate in combination with the antifolates sulfadoxine-pyrimethamine (SP) has been first-line treatment for uncomplicated falciparum malaria until 2016. Although SP has been the recommended treatment for falciparum and not vivax malaria, exposure of the P. vivax parasite population to SP might still have been quite extensive because of community based management of malaria. The change in the P. vivax antifolate resistance markers between 2007 and 2017 were investigated.

Systematic review and meta-analysis of diagnostic accuracy of Loop-mediated isothermal amplification (LAMP) methods compared to microscopy, PCR, and rapid diagnostic tests, for malaria diagnosis

July 14, 2020 - 15:50 -- Open Access
Author(s): 
Picot S, Cucherat M, Bienvenu AL
Reference: 
Int J Infect Dis. 2020 Jul 10:S1201-9712(20)30551-8

Diagnosis is a challenging issue in the way to malaria elimination. LAMP could be an alternative to conventional methods. Then, it is of interest to evaluate the diagnostic accuracy of LAMP for malaria compared to microscopy, PCR, and RDTs.

Droplet digital polymerase chain reaction (ddPCR) for the detection of Plasmodium knowlesi and Plasmodium vivax

July 14, 2020 - 09:19 -- Open Access
Author(s): 
Punitha Mahendran, Jonathan Wee Kent Liew, Amirah Amir, Xiao-Teng Ching and Yee-Ling Lau
Reference: 
Malaria Journal 2020 19:241, 10 July 2020

Plasmodium knowlesi and Plasmodium vivax are the predominant Plasmodium species that cause malaria in Malaysia and play a role in asymptomatic malaria disease transmission in Malaysia. The diagnostic tools available to diagnose malaria, such as microscopy and rapid diagnostic test (RDT), are less sensitive at detecting lower parasite density. Droplet digital polymerase chain reaction (ddPCR), which has been shown to have higher sensitivity at diagnosing malaria, allows direct quantification without the need for a standard curve. The aim of this study is to develop and use a duplex ddPCR assay for the detection of P. knowlesi and P. vivax, and compare this method to nested PCR and qPCR.

Genetic diversity and neutral selection in Plasmodium vivax erythrocyte binding protein correlates with patient antigenicity

July 13, 2020 - 16:27 -- Open Access
Author(s): 
Han JH, Cho JS, Han ET, et al.
Reference: 
PLoS Negl Trop Dis 14(7): e0008202

Plasmodium vivax is the most widespread and difficult to treat cause of human malaria. The development of vaccines against the blood stages of P. vivax remains a key objective for the control and elimination of vivax malaria. Erythrocyte binding-like (EBL) protein family members such as Duffy binding protein (PvDBP) are of critical importance to erythrocyte invasion and have been the major target for vivax malaria vaccine development.

Plasmodium vivax AMA1: Implications of distinct haplotypes for immune response

July 9, 2020 - 08:45 -- Open Access
Author(s): 
Bittencourt NC, da Silva ABIE, Albrecht L, et al.
Reference: 
PLoS Negl Trop Dis 14(7): e0008471

In Brazil, Plasmodium vivax infection accounts for around 80% of malaria cases. This infection has a substantial impact on the productivity of the local population as the course of the disease is usually prolonged and the development of acquired immunity in endemic areas takes several years. The recent emergence of drug-resistant strains has intensified research on alternative control methods such as vaccines.

NOT Open Access | The extent of chloroquine underdosing in adult patients with malaria by Plasmodium vivax from an endemic area of the Brazilian Amazon basin

July 8, 2020 - 15:42 -- NOT Open Access
Author(s): 
Valéria Dias Ferreira M, Gabryelle Nunes Cardoso Mello A, Wendel Pereira de Sena L, Regina Matos Lopes T, Luiz Fernandes Vieira J
Reference: 
Trop Med Int Health. 2020 Jul 7

To evaluate the extent of chloroquine underdosing and to measure the concentrations of chloroquine and desethylchloroquine in adult patients with P. vivax malaria in the Brazilian Amazon basin.

Pages

Subscribe to RSS - Plasmodium vivax